(Q30788774)

26 June 2017

1 reference

title

Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments (English)

1 reference

glucocorticoid-induced osteoporosis

26 June 2017

0 references

0 references

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(03)00016-2

Marie-Helene Lafage-Proust

27 December 2023

author

1

object named as

Marie Hélène Lafage-Proust

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12713854

27 December 2023

author name string

Benjamin Boudignon

2

1 reference

26 June 2017

Thierry Thomas

3

1 reference

26 June 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12713854

27 December 2023

publication date

1 March 2003

1 reference

full work available at URL

26 June 2017

https://api.elsevier.com/content/article/PII:S1297319X03000162?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(03)00016-2

https://api.elsevier.com/content/article/PII:S1297319X03000162?httpAccept=text/plain

27 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(03)00016-2

27 December 2023

1 reference

26 June 2017

volume

70

1 reference

26 June 2017

issue

2

1 reference

26 June 2017

page(s)

109-118

1 reference

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Use of oral corticosteroids and risk of fractures.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Inhaled corticosteroids reduce bone mineral density in early postmenopausal but not premenopausal asthmatic women

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

One year prospective open study of the effect of high dose inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Short-term effects of corticosteroids on trabecular bone remodeling in old ewes

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Effects of continuous glucocorticoid infusion on bone metabolism in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Effect of low-dose methylprednisolone on calcium balance and bone composition in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Reduction of serum-1, 25-dihydroxyvitamin-D3 in children receiving glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Low-dose prednisone therapy in rheumatoid arthritis: effect on vitamin D metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Short-term effect of prednisone on serum 1,25-dihydroxyvitamin D in normal individuals and in hyper- and hypoparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Prevention of corticosteroid-induced osteoporosis by alfacalcidol

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

The effect of long- and short-term corticosteroids on plasma calcitonin and parathyroid hormone levels.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Glucocorticoids stimulate resorption in fetal rat parietal bones in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Glucocorticoids impair bone resorptive activity and viability of osteoclasts disaggregated from neonatal rat long bones

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Bone loss in response to long-term glucocorticoid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

The effects of dexamethasone and 1,25-dihydroxyvitamin D3 on osteogenic differentiation of human marrow stromal cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Reduction in transforming growth factor beta receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Determination of the capacity for proliferation and differentiation of osteoprogenitor cells in the presence and absence of dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Tandem repeat of C/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-induced adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Cortisol downregulates osteoblast alpha 1 (I) procollagen mRNA by transcriptional and posttranscriptional mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Glucocorticoids inhibit the attachment of osteoblasts to bone extracellular matrix proteins and decrease beta 1-integrin levels

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Cortisol Increases Interstitial Collagenase Expression in Osteoblasts by Post-transcriptional Mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

1,25-Dihydroxyvitamin D reduces parathyroid hormone receptor number in ROS 17/2.8 cells and prevents the glucocorticoid-induced increase in these receptors: Relationship to adenylate cyclase activation

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Glucocorticoids regulate the expression of the human osteoblastic endothelin A receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Testosterone levels during systemic and inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Risk of osteoporosis in men with chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Relations between steroid hormones and cytokines in rheumatoid arthritis and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

The relation between plasma androstenedione and oestrone levels in untreated and corticosteroid-treated post-menopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Nitric oxide and bone

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Effect of calcitriol on bone loss after cardiac or lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Dehydroepiandrosterone in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Salmon calcitonin in the therapy of corticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2803%2900016-2

7 January 2021

A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists

3

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(03)00016-2

Prednisone-induced osteopenia in beagles: variable effects mediated by differential suppression of bone formation

27 December 2023

40

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(03)00016-2

Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids

27 December 2023

69

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(03)00016-2

Decreased testosterone levels in men with rheumatoid arthritis: effect of low dose prednisone therapy

27 December 2023

70

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(03)00016-2

Weak androgen levels, glucocorticoid therapy, and bone mineral density in postmenopausal women with rheumatoid arthritis

27 December 2023

76

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(03)00016-2

Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis

27 December 2023

111

1 reference

https://api.crossref.org/works/10.1016/S1297-319X(03)00016-2

27 December 2023

Identifiers

1 reference

26 June 2017

1 reference